Products for Research Use Only
RegisterLogin

Satraplatin

CAT: 0013-GTR19163910-07Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19163910-07Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM) ; shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active.Chemotherapeutic Agents, Phase 2 Clinical (In Vitro) :Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC50 of 1.36 ± 0.11 μM. Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC50, 7.04 μM), and causes G2/M arrest in KB-R cells.
CAS Number
129580-63-8
Product Name Alternative
BMS-182751 | BMY-45594 | JM-216
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 33 mg/mL
Smiles
CC (O[Pt] ([NH2]C1CCCCC1) (Cl) (Cl) ([NH3]) OC (C) =O) =O
Molecular Formula
C10H22Cl2N2O4Pt+2
Molecular Weight
500.2816
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Platinum, bis (acetato-κO) amminedichloro (cyclohexanamine) -, (OC-6-43) - (9CI)

Chemical Information

Satraplatin

Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

CAS Number129580-63-8
PubChem CID123974
IUPAC Nameazane;cyclohexanamine;platinum(4+);diacetate;dichloride
Molecular FormulaC10H22Cl2N2O4Pt
Molecular Weight500.3
Topological Polar Surface Area107
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count0
Heavy Atom Count19
Formal Charge0
Complexity71
SMILES
CC(=O)[O-].CC(=O)[O-].C1CCC(CC1)N.N.[Cl-].[Cl-].[Pt+4]
InChI
InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
InChIKey
CKNPWBAXEKSCRG-UHFFFAOYSA-J
Chemical Structure
2D Structure
2D structure of Satraplatin
CAS: 129580-63-8
CID: 123974
Formula: C10H22Cl2N2O4Pt
MW: 500.3
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight500.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count0
Exact Mass499.060457
Monoisotopic Mass499.060457
Topological Polar Surface Area107 Ų
Heavy Atom Count19
Formal Charge0
Complexity71.7
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count7
Compound Is CanonicalizedYes

Alternative Products

CatalogName
BA3931-5Satraplatin
A20974-25Satraplatin 25mg
A20974-5Satraplatin 5mg
A20974-10Satraplatin 10mg
A20974-100Satraplatin 100mg
A20974-50Satraplatin 50mg
A20974-1Satraplatin 1mg

Popular Products